TABLE II -.
Costs and benefits for ALK diagnosed and ALK non-diagnosed patients with NSCLC
| Diagnosed patients | Non-diagnosed patients | Difference | |
|---|---|---|---|
| Costs | |||
| ALK diagnosis | €1,111,783 | €0 | €1,111,783 |
| Drugs | €50,792,934 | €42,602,890 | €8,190,044 |
| Drug administration | €104,629 | €265,774 | −€161,145 |
| Follow-up resources | €8,344,028 | €5,615,785 | €2,728,243 |
| Treating adverse events | €374,265 | €1,000,223 | −€625,958 |
| Formal care | €18,004 | €42,931 | −€24,927 |
| Informal care | €745,014 | €1,831,910 | −€1,086,896 |
| Traveling (visits and administration) | €422,944 | €364,589 | €58,355 |
| Productivity loss due to attendance visits and follow-up tests | €7,184 | €6,419 | €766 |
| Total costs | €61,920,785 | €51,730,521 | €10,190,265 |
| Benefits | |||
| Stigmatization and guilt | −€17,686 | −€63,540 | €45,854 |
| QoL loss associated with progression | −€513,869 | −€469,177 | −€44,692 |
| QoL loss associated with mortality | −€8,174,452 | −€14,183,585 | €6,009,133 |
| Adverse events | −€456,325 | −€1,381,624 | €925,299 |
| Time to spend with the family | −€4,214,901 | −€7,399,309 | €3,184,408 |
| QoL of caregivers | −€345,122 | −€404,806 | €59,684 |
| Productivity loss due to sick leave | −€6,880,171 | −€5,500,661 | −€1,379,510 |
| Productivity loss due to premature death | −€3,115,468 | −€6,027,573 | €2,912,105 |
| Total benefits | −€2,371,799 | −€35,430,276 | €11,712,282 |
| Cost-benefit ratio | €1.15 |
ALK = anaplastic lymphoma kinase; NSCLC = non–small cell lung cancer; QoL = quality of life.